Summary of COVID-19 empagliflozin studies

1. Horby et al., Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

4,271 patient empagliflozin late treatment RCT: 4% lower mortality (p=0.59), 3% lower ventilation (p=0.77), and 3% higher hospital discharge (p=0.44).
RCT 4,271 hospitalized COVID-19 patients showing no significant difference in outcomes with empagliflozin treatment. 6-month results are from [Horby]
Dec 2023, The Lancet Diabetes & Endocrinology, https://www.sciencedirect.com/science/article/pii/S221385872300253X, https://c19p.org/horby4